HCPCS Code Q0235
Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
Miscellaneous Services (Temporary Codes)
Q0235 is a valid 2026 HCPCS code for Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg or just “Inj, monoclon antibody, 1 mg” for short, used in Pneumococcal/flu vaccine.
| HCPCS Level II Code Miscellaneous Services (Temporary Codes) |
|
| HCPCS Code | Q0235 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Modifier1 | |
| HCPCS Pricing indicator |
54 - Vaccinations
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1G - Immunizations/Vaccinations |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | V - Pneumococcal/flu vaccine |
| Effective date | Effective Oct 01, 2025 |
| Date added | Added Oct 01, 2025 |
| HCPCS Coding Procedures | |
HCPCS Modifiers
In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.
Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
“NU” identifies the hospital bed as new equipment
See also
-
HCPCS Q0224 · Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
-
HCPCS Q0237 · Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
